{"id":863163,"date":"2025-06-24T09:53:04","date_gmt":"2025-06-24T13:53:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/"},"modified":"2025-06-24T09:53:04","modified_gmt":"2025-06-24T13:53:04","slug":"bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/","title":{"rendered":"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy"},"content":{"rendered":"

<\/p>\n

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy<\/b><\/p>\n

Company research targets topical application for treatment of skin cancers<\/i><\/p>\n

SAN ANTONIO, Texas–(BUSINESS WIRE<\/a>)–bioAffinity Technologies, Inc.<\/b><\/a> (Nasdaq: BIAF; BIAFW)<\/b>, a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company\u2019s novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane.<\/p>\n

\nThe newly allowed Chinese patent \u2013 titled \u201cCompositions and Methods for Treating Cancer\u201d \u2013 adds important global protection for bioAffinity\u2019s innovative RNA-based therapeutic strategy and covers siRNAs and their use in cancer treatment, which is also protected by the Company\u2019s new U.S. Patent No. 12,305,171.<\/p>\n

\nThe invention uses small interfering RNAs (siRNAs) to suppress the expression of CD320 and LRP2 proteins. In vitro research demonstrates this siRNA-driven double knockdown effectively targets cancer cells from multiple tumor types, including lung, breast, prostate, brain, and skin, without harming normal cells, suggesting a universal mechanism of action.<\/p>\n

\nbioAffinity is exploring the application of this technology as a topical treatment specifically designed for cutaneous malignancies and neoplasms of the skin. This development aligns closely with the Company’s broader strategy of addressing cancer through both early-stage diagnostics, exemplified by CyPath\u00ae Lung, and innovative therapeutic approaches.<\/p>\n

\n\u201cThis newly allowed patent expands our global intellectual property portfolio and strengthens our position in developing siRNA-based therapies that exploit a fundamental vulnerability in cancer cells,\u201d said William Bauta, PhD, Chief Science Officer at bioAffinity Technologies. \u201cOur research has shown that silencing CD320 and LRP2 leads to cancer cell death without harming normal cells \u2013 a highly selective approach with potential for broad therapeutic application.\u201d<\/p>\n

\nbioAffinity continues to advance its high-growth core diagnostic platform, CyPath\u00ae Lung, an accurate, noninvasive test for early-stage lung cancer detection, while simultaneously leveraging its scientific expertise toward novel therapeutic solutions that address critical unmet medical needs in oncology.<\/p>\n

About CyPath\u00ae Lung<\/b><\/p>\n

\nCyPath\u00ae Lung uses proprietary advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. Automated data analysis helps determine if cancer is present or if the patient is cancer-free. CyPath\u00ae Lung incorporates a fluorescent porphyrin that is preferentially taken up by cancer and cancer-related cells. Clinical study results<\/a> demonstrated that CyPath\u00ae Lung had 92% sensitivity, 87% specificity and 88% accuracy in detecting lung cancer in patients at high risk for the disease who had small lung nodules less than 20 millimeters. Diagnosing and treating early-stage lung cancer can improve outcomes and increase patient survival. For more information, visit www.cypathlung.com<\/a>.<\/p>\n

About bioAffinity Technologies, Inc.<\/b><\/p>\n

\nbioAffinity Technologies, Inc. addresses the need for noninvasive diagnosis of early-stage cancer and other diseases of the lung and broad-spectrum cancer treatments. The Company\u2019s first product, CyPath\u00ae Lung<\/a>, is a noninvasive test that has shown high sensitivity, specificity and accuracy for the detection of early-stage lung cancer. CyPath\u00ae Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services<\/a>, a subsidiary of bioAffinity Technologies. For more information, visit www.bioaffinitytech.com<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nCertain statements in this press release constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements regarding developing siRNA-based therapies that exploit a fundamental vulnerability in cancer cells, silencing CD320 and LRP2 leading to cancer cell death without harming normal cells, and the dual knockdown of CD320 and LRP2 using siRNA, suggesting a universal mechanism of action. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company\u2019s ability to develop siRNA-based therapies across multiple cancer types and other factors discussed in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2024, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20250624870760\/en\/<\/a><\/span><\/p>\n

bioAffinity Technologies
\n<\/b>
Julie Anne Overton
\n
Director of Communications
\n
jao@bioaffinitytech.com<\/a><\/p>\n

KEYWORDS:<\/b> China United States North America Asia Pacific Texas<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Health Health Technology Genetics General Health Pharmaceutical Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy Company research targets topical application for treatment of skin cancers SAN ANTONIO, Texas–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company\u2019s novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The newly allowed Chinese patent \u2013 titled \u201cCompositions and Methods for Treating Cancer\u201d \u2013 adds important global protection for bioAffinity\u2019s innovative RNA-based therapeutic strategy and covers siRNAs and their use in cancer treatment, which is also protected by the … <\/p>\n

Continue reading “bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-863163","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nbioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy Company research targets topical application for treatment of skin cancers SAN ANTONIO, Texas–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company\u2019s novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The newly allowed Chinese patent \u2013 titled \u201cCompositions and Methods for Treating Cancer\u201d \u2013 adds important global protection for bioAffinity\u2019s innovative RNA-based therapeutic strategy and covers siRNAs and their use in cancer treatment, which is also protected by the … Continue reading "bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-24T13:53:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy\",\"datePublished\":\"2025-06-24T13:53:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/\"},\"wordCount\":874,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/\",\"name\":\"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2025-06-24T13:53:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/","og_locale":"en_US","og_type":"article","og_title":"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy - Market Newsdesk","og_description":"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy Company research targets topical application for treatment of skin cancers SAN ANTONIO, Texas–(BUSINESS WIRE)–bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage diagnostics and targeted therapeutics for cancer, today announced that the China National Intellectual Property Administration (CNIPA) has issued a notification of patent grant for the company\u2019s novel composition and method for selectively killing cancer by targeting the CD320 and LRP2 receptors on the cell membrane. The newly allowed Chinese patent \u2013 titled \u201cCompositions and Methods for Treating Cancer\u201d \u2013 adds important global protection for bioAffinity\u2019s innovative RNA-based therapeutic strategy and covers siRNAs and their use in cancer treatment, which is also protected by the … Continue reading \"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/","og_site_name":"Market Newsdesk","article_published_time":"2025-06-24T13:53:04+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy","datePublished":"2025-06-24T13:53:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/"},"wordCount":874,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/","name":"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en","datePublished":"2025-06-24T13:53:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20250624870760r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bioaffinity-technologies-expands-patent-portfolio-with-china-grant-for-sirna-based-cancer-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"bioAffinity Technologies Expands Patent Portfolio with China Grant for siRNA-Based Cancer Therapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/863163","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=863163"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/863163\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=863163"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=863163"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=863163"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}